CClinicalTrials.gg
Sign In
CompletedNCT02739061Updated Jan 7, 2020

The Study of the Pathogenesis and Cognitive Behavioral Group Therapy in Obsessive-Compulsive Disorder

An interventional study of cognitive behavioral group therapy and sertraline, fluvoxamine in Obsessive-Compulsive Disorder, sponsored by Shanghai Mental Health Center. Completed at 1 site in China. Open to participants aged 18 Years to 54 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-07.

Sponsored by Shanghai Mental Health Center · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 10 months after the study started (first participant enrolled Jun 2014, registered Apr 2016).
Phase
Not applicable
Study type
Interventional
Enrollment
142
Allocation
Randomized
Ages
18 Years to 54 Years
Sex
All
01

Study summary

This study intends to explore the pathogenesis of obsessive-compulsive disorder(OCD) by using biological technologies such as genetics and imaging, and to evaluate the efficacy of group cognitive behavioural therapy in OCD among the Chinese people. We also prepare to explore the synergistic effect of the pharmacological treatment combined with group cognitive behavioural therapy in OCD, and to find the biological and psychological index which can predict curative effect.

This research includes case control study and randomized controlled single-blind study. At baseline, we compare the dimensions of clinical symptoms, genetics and imaging between OCD patients and healthy controls. The OCD patients are randomly assigned into pharmacological treatment, psychological treatment or pharmacological combined with psychological treatment for a 12-week treatment. After a 12-week treatment, the OCD patients will be divided into valid and invalid groups according to the results of our randomized controlled study by researchers: to our valid group, patients will continue the current treatment, and to the invalid psychological or pharmacological treatment group, patients will have a 12-week combined treatment. From the baseline, we will have a 9-month follow up for both OCD patients and healthy controls.

Read the detailed description
  1. Case control study: At baseline, comparing the dimensions of clinical symptoms, genetics and imaging between OCD patients and healthy controls who were chosen into our study.
  2. Randomized controlled single-blind study: The OCD patients are randomly assigned into pharmacological treatment, psychological treatment or pharmacological combined with psychological treatment. Psychological treatment: every six or so patients can establish a closed structured group. Each group will be treated for 12 sessions, for once a week, 120 minutes at a time. The 1-3 session will be psychological education on the topic of OCD and cognitive behavioral therapy; The 4-6 and 8-10 session will do step by step exposure and response prevention(ERP) training; the 7th an 11th session will invite family members or other caregivers of OCD patients for a education about OCD cognitive behavioral therapy to facilitate patients to complete ERP homework and give them some social supports; the final session will be self treatment evaluation and long-term treatment guidance. Pharmacological treatment: This study choose the SSRIs(Selective Serotonin Reuptake Inhibitor:sertraline, fluvoxamine, initial dose of 50 mg, the dose can be adjusted once a week, and the maximum dose should under the instruments ) approved by SFDA(China Food and Drug Administration) for OCD treatment which will last 12 weeks. Patients with sleep disorder can combined with Benzodiazepines less than two consecutive weeks; combination with other psychotropic drugs are forbidden. Pharmacological combined with psychological treatment: every six or so patients can establish a closed structured group which is same as the psychological treatment group; patients start to take medicine at the same time, use of the medicine is same as the pharmacological treatment group.
  3. Follow-up study: After finishing the 12-week treatment, the OCD patients will be into a 6-month follow-up. Patients who are satisfied with pharmacological and/or psychological treatment will continue the current treatment, while others' follow-up treatment and specific treatment ways will be decided by researchers through the results of of our randomized controlled study. Our randomized controlled study results will be divided into valid and invalid groups. To the invalid psychological or pharmacological treatment group, patients will have a 12-week combined treatment which means invalid pharmacological treatment need to combine with psychological treatment and invalid psychological treatment need to combine with pharmacological treatment. Invalid pharmacological combined with psychological treatment should adjust the medicine (change with sertraline/fluvoxamine) and go on the psychological treatment. After the baseline assessment, OCD patients will have a follow-up evaluation at the 16th, 24th, and 36th week, while the healthy control will have a follow-up evaluation at the 12th and 36th week.
02

Conditions studied

  • Obsessive-Compulsive Disorder

Keywords

  • pathogenesis
  • cognitive behavioral group therapy
03

In context

Compulsive Personality Disorder

367 studies on the registry are indexed under Compulsive Personality Disorder; 67 are open to participants now.

This study's enrollment of 142 is above the median of 37 across 306 interventional studies indexed under Compulsive Personality Disorder.

Browse Compulsive Personality Disorder studies →

Lead sponsor

Shanghai Mental Health Center is the lead sponsor of 267 studies on the registry; 93 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 54 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • OCD patients： Among 18 to 54 years old, males or females； See a doctor because of OCD recently，conform to DSM-Ⅳ(Diagnostic and Statistical Manual of Mental Disorders) diagnostic criteria of OCD; The scores of the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) is not less than 16 points; Has not yet accepted psychiatric medication or have received irregular medication treatments and discontinuation for at least eight weeks; A junior high school and above level of education; Has enough of seeing and hearing level to complete the necessary checks; Right-handed (this standard is limited to magnetic resonance imaging (MRI) detection); The Han nationality (this standard is limited to genetic testing); Willing to participate in this study..
  • Healthy controls： 1:1 match with the OCD group in age, gender and level of education; Never appear symptoms of OCD, not comply with obsessive compulsive disorder, or other mental disorders DSM-Ⅳ diagnostic criteria; There is no history of psychiatric medication; No two lines three generations of history of mental disorder; Has enough of seeing and hearing level to complete the necessary checks; Right-handed (this standard is limited to magnetic resonance imaging (MRI) detection); The Han nationality (this standard is limited to genetic testing); Willing to participate in this study.

Exclusion criteria

Exclusion Criteria:

  • OCD patients： Conform to the DSM-Ⅳ other axis I except obsessive-compulsive disorder diagnosis (M.I.N.I evaluation screening); Patients will not be able to complete the required assessment check and cognitive behavioural therapy because of the severe OCD symptoms; There is negative or a higher risk of suicide; Currently suffering from serious physical disease or central nervous system disease, substance abuse; Pregnant woman or woman who is ready to be pregnant, and lactating women; Used to have received a full course of cognitive behavioral therapy, and no significant curative effect; In presence of metallic implants: install pacemaker, intracranial silver clip, metal false teeth, stents, artery clamp, joints, metal fixed, or other metal implants in (this standard is limited to magnetic resonance imaging (MRI) detection).
  • Healthy controls： There is negative or a higher risk of suicide; Currently suffering from serious physical disease or central nervous system disease, substance abuse; Pregnant woman or woman who is ready to be pregnant, and lactating women; In presence of metallic implants: install pacemaker, intracranial silver clip, metal false teeth, stents, artery clamp, joints, metal fixed, or other metal implants in (this standard is limited to magnetic resonance imaging (MRI) detection).
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
142 participants (actual)

Study arms

  • Active comparator
    cognitive behavioral group therapy

    cognitive behavioral group therapy

    Behavioral: cognitive behavioral group therapy

  • Active comparator
    drug therapy

    drug therapy

    Drug: sertraline, fluvoxamine

  • Active comparator
    The combination therapy

    cognitive behavioral group therapy and drug therapy

    Other: cognitive behavioral group therapy and drug therapy

Interventions

  • Behavioralcognitive behavioral group therapy

    Establish closed every collection of six or so patients structured group. Each group patients were treated for 12 times, once a week, 120 minutes at a time. Treatment for 1 to 3 times to obsessive-compulsive disorder and cognitive behavioral therapy as the theme of psychological education; 4 to 6, 8 to 10 times exposed step by step and reaction treatment and prevention of training;7 and 11 times invite patients family members or other caregivers, make education about obsessive-compulsive disorder cognitive behavioural therapy, to promote patients exposed response prevention homework completion and social support; The 12th time treatment is self assessment and treatment guidelines for a long time.

  • Drugsertraline, fluvoxamine

    Select specified drugs (sertraline, fluvoxamine)

  • Othercognitive behavioral group therapy and drug therapy

    Select specified drugs (sertraline, fluvoxamine) and start group cognitive behavior therapy for 12 weeks at the same time

06

What researchers measure

Primary outcomes

  1. Y-BOCS (The Yale-Brown Obsessive Compulsive Scale)

    Time frame: up to 6 months after treatment

07

Study locations

1 site
  • Clinical psychiatrist
    Shanghai, Shanghai 200030, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 7, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02739061
Lead sponsor
Shanghai Mental Health Center
Responsible party
Sponsor
First posted
Apr 14, 2016
Start date
Jun 12, 2014
Primary completion
Mar 8, 2017
Completion
Jul 24, 2017
Last update
Jan 7, 2020

Study contacts

Yifeng Shen, Senior
study director · Shanghai Mental Health Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Compulsive Personality Disorder→

Other studies from this sponsor

Shanghai Mental Health Center

Start the discussion